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Proper spatial differentiation of retinal cell types is necessary for normal human vision. Many retinal
diseases, such as Best disease and male germ cell associated kinase (MAK)-associated retinitis pigmen-
tosa, preferentially affect distinct topographic regions of the retina. While much is known about the
distribution of cell types in the retina, the distribution of molecular components across the posterior pole
of the eye has not been well-studied. To investigate regional difference in molecular composition of
ocular tissues, we assessed differential gene expression across the temporal, macular, and nasal retina
and retinal pigment epithelium (RPE)/choroid of human eyes using RNA-Seq. RNA from temporal,
macular, and nasal retina and RPE/choroid from four human donor eyes was extracted, poly-A selected,
fragmented, and sequenced as 100 bp read pairs. Digital read ﬁles were mapped to the human genome
and analyzed for differential expression using the Tuxedo software suite. Retina and RPE/choroid samples
were clearly distinguishable at the transcriptome level. Numerous transcription factors were differen-
tially expressed between regions of the retina and RPE/choroid. Photoreceptor-speciﬁc genes were
enriched in the peripheral samples, while ganglion cell and amacrine cell genes were enriched in the
macula. Within the RPE/choroid, RPE-speciﬁc genes were upregulated at the periphery while endothe-
lium associated genes were upregulated in the macula. Consistent with previous studies, BEST1
expression was lower in macular than extramacular regions. TheMAK gene was expressed at lower levels
in macula than in extramacular regions, but did not exhibit a signiﬁcant difference between nasal and
temporal retina. The regional molecular distinction is greatest between macula and periphery and de-
creases between different peripheral regions within a tissue. Datasets such as these can be used to
prioritize candidate genes for possible involvement in retinal diseases with regional phenotypes.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
Human visual activities balance the need for high visual acuity,
such as reading, driving, and recognizing faces, with comprehen-
sive peripheral vision. High visual acuity is enabled by themacula, aERF, The University of Iowa,
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Ltd. This is an open access article uregion at the center of the posterior retina with the highest density
of cone photoreceptors and ganglion cells. Vision in dim light is
made possible by the rod photoreceptor cells which are most
concentrated just anterior to the macula.
Many ocular pathologies affect distinct regions of the retina.
Macular degenerations, such as age-related macular degeneration,
Best disease, Stargardt disease, and North Carolina macular dys-
trophy, result in loss of photoreceptors and RPE cells in the macula.
Other diseases, such as retinitis pigmentosa (RP), cause selective
loss of photoreceptors at the periphery of the retina, often sparing
central vision until advanced stages of disease. Some diseases
manifest further distinction in regional phenotypes. For instance,
male germ cell associated kinase (MAK)-related RP, the most
common cause of inherited blindness among the Ashkenazi Jewishnder the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
Table 1
Donor information. Samples marked by asterisks (*) were analyzed for differential expression in Cuffdiff. Library prep involved poly-A selection.
Donor Eye Sex Age Cause of death Death-to-preservation (h) Retina RPE/choroid Library prep.
1* OS F 82 Respiratory failure <4 M, N, T M, N, T stranded
2* OD M 77 Congestive heart failure <5 M, N, T M, N, T stranded
3* OD F 89 Pneumonia 3e4.5 M, N, T M, N, T stranded
4* OS M 91 Pneumonia 5e6 M, N, T M, N, T stranded
5 OD F 91 Unknown <6 M, N, T, S, I e unstranded
Abbreviations: M macula; N e nasal; T e temporal; S e superior; I e inferior.
Fig. 1. Hierarchical clustering on expressed isoforms based on Spearman's correlation.
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Fig. 2. Comparison of GWAS associated gene sets with data published by Li et al. (2014).
accounting for the number of genes in RPE/choroid below the diagonal. Spearman rank co
S.S. Whitmore et al. / Experimental Eye Research 129 (2014) 93e10694population, manifests an unusual inferonasal predilection for the
photoreceptor cell death (Stone et al., 2011; Tucker et al., 2011).
Classic studies on the distribution of cell types through the
neural retina (Curcio and Allen,1990; Curcio et al., 1990; Jonas et al.,
1992), combined with extensive disease phenotyping and detailed
analyses of single molecule expression have provided substantial
insight into the structural and functional organization of the neural
retina, retinal pigment epithelium (RPE), and choroid in different
regions of the eye. Previous large-scale studies aimed at differen-
tiating macula from periphery have utilized reverse transcriptase-
polymerase chain reaction (RT-PCR) (Kociok and Joussen, 2007),
array-based technologies (Ishibashi et al., 2004; Diehn et al., 2005;
Bowes Rickman et al., 2006; Radeke et al., 2007; van Soest et al.,
2007) and more recently, RNA sequencing (RNA-Seq) (Li et al.,
2014). Unlike the former two technologies, RNA-Seq provides not
only estimates of gene expression level and isoform abundance, but
also captures sequence-level information, potentially uncovering
novel exons and other transcriptional events.periphery
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The previously published dataset included sclera in the RPE/choroid punches, likely
rrelation coefﬁcient shown (r).
Table 2
Top 40 differentially expressed genes between nasal retina vs. macular retina with q-value < 0.001 and absolute log2(fold-change)  1.
Symbol Description Chromosome Start Stop Macular
retina (FPKM)
Nasal
retina (FPKM)
Log2(FC) P-value Q-value
HSD17B2 Hydroxysteroid (17-beta)
dehydrogenase 2
chr16 82,056,731 82,132,139 1.29 9.55 2.88 5.00E-05 2.86E-04
CYP26B1 Cytochrome P450, family 26, subfamily
B, polypeptide 1
chr2 72,356,363 72,375,687 0.41 2.77 2.75 5.00E-05 2.86E-04
COL2A1 Collagen, type II, alpha 1 chr12 48,366,747 48,398,285 1.56 9.98 2.68 5.00E-05 2.86E-04
STEAP4 STEAP family member 4 chr7 87,900,209 87,936,319 0.31 1.89 2.58 5.00E-05 2.86E-04
FOXI3 Forkhead box I3 chr2 88,744,347 88,752,197 0.49 2.81 2.51 5.00E-05 2.86E-04
OXTR Oxytocin receptor chr3 8,792,094 8,811,460 0.49 1.91 1.96 5.00E-05 2.86E-04
NPVF Neuropeptide VF precursor chr7 25,264,190 25,268,105 29.12 106.31 1.87 5.00E-05 2.86E-04
ZIC1 Zic family member 1 chr3 147,103,834 147,134,784 1.24 4.25 1.78 5.00E-05 2.86E-04
PRL Prolactin chr6 22,287,472 22,303,082 4.48 15.15 1.76 5.00E-05 2.86E-04
LOXL4 Lysyl oxidase-like 4 chr10 100,007,442 100,028,007 0.98 3.20 1.71 1.00E-04 5.49E-04
FXYD2a FXYD domain containing ion transport
regulator 2
chr11 117,690,789 117,748,201 12.05 35.28 1.55 5.00E-05 2.86E-04
KRT39b Keratin 39 chr17 39,113,368 39,143,387 3.43 10.02 1.55 5.00E-05 2.86E-04
ID3 Inhibitor of DNA binding 3, dominant
negative helix-loop-helix protein
chr1 23,884,420 23,886,285 17.01 48.24 1.50 5.00E-05 2.86E-04
EGR1 Early growth response 1 chr5 137,801,180 137,805,004 15.34 39.41 1.36 5.00E-05 2.86E-04
HTR1F 5-hydroxytryptamine (serotonin)
receptor 1F, G protein-coupled
chr3 87,841,874 88,049,226 0.78 2.00 1.35 5.00E-05 2.86E-04
CSRP2 Cysteine and glycine-rich protein 2 chr12 77,252,493 77,272,799 19.34 48.16 1.32 5.00E-05 2.86E-04
CYR61 Cysteine-rich, angiogenic inducer, 61 chr1 86,046,443 86,049,648 11.76 29.12 1.31 5.00E-05 2.86E-04
LGALS3 Lectin, galactoside-binding, soluble, 3 chr14 55,595,934 55,612,148 16.89 41.31 1.29 5.00E-05 2.86E-04
C4Ac Complement component 4A (Rodgers
blood group)
chr6 31,982,571 32,003,195 1.25 3.02 1.27 1.00E-04 5.49E-04
NR4A1 Nuclear receptor subfamily 4, group A,
member 1
chr12 52,416,615 52,453,292 15.05 36.28 1.27 1.50E-04 8.01E-04
KCNC2 Potassium voltage-gated channel,
Shaw-related subfamily, member 2
chr12 75,433,857 75,603,528 57.75 17.88 1.69 5.00E-05 2.86E-04
Potentially novel chr6 113,745,551 113,755,041 13.32 4.05 1.72 5.00E-05 2.86E-04
TRPM2 Transient receptor potential cation
channel, subfamily M, member 2
chr21 45,770,087 45,869,277 8.60 2.60 1.72 5.00E-05 2.86E-04
RIT2 Ras-like without CAAX 2 chr18 40,323,182 40,695,841 13.61 4.11 1.73 5.00E-05 2.86E-04
ISLR2 Immunoglobulin superfamily
containing leucine-rich repeat 2
chr15 74,418,236 74,429,152 15.76 4.72 1.74 5.00E-05 2.86E-04
AHNAK2 AHNAK nucleoprotein 2 chr14 105,371,613 105,444,694 84.49 25.19 1.75 1.00E-04 5.49E-04
IRX2 Iroquois homeobox 2 chr5 2,745,916 2,751,769 14.95 4.34 1.78 5.00E-05 2.86E-04
CPNE9 Copine family member IX chr3 9,745,509 9,771,592 5.89 1.70 1.79 5.00E-05 2.86E-04
TTC39A Tetratricopeptide repeat domain 39A chr1 51,752,172 51,810,785 22.16 6.24 1.83 5.00E-05 2.86E-04
HTR1B 5-hydroxytryptamine (serotonin)
receptor 1B, G protein-coupled
chr6 78,168,875 78,174,100 3.40 0.95 1.84 1.50E-04 8.01E-04
PHOSPHO1 Phosphatase, orphan 1 chr17 47,300,731 47,308,128 6.47 1.81 1.84 5.00E-05 2.86E-04
FABP3 Fatty acid binding protein 3, muscle and
heart (mammary-derived growth
inhibitor)
chr1 31,769,837 31,846,528 131.10 35.95 1.87 5.00E-05 2.86E-04
PTH1R Parathyroid hormone 1 receptor chr3 46,761,072 46,945,351 11.74 3.18 1.88 1.00E-04 5.49E-04
LCP1 Lymphocyte cytosolic protein 1 (L-
plastin)
chr13 46,700,056 46,785,977 7.48 1.94 1.95 5.00E-05 2.86E-04
SLN Sarcolipin chr11 107,578,100 107,582,787 42.78 10.92 1.97 5.00E-05 2.86E-04
MCTP1 Multiple C2 domains, transmembrane 1 chr5 94,036,882 94,620,279 3.33 0.84 2.00 5.00E-05 2.86E-04
MRGPRE MAS-related GPR, member E chr11 3,246,156 3,254,111 12.08 2.58 2.22 5.00E-05 2.86E-04
RASGRP3 RAS guanyl releasing protein 3 (calcium
and DAG-regulated)
chr2 33,630,960 33,792,285 5.84 1.09 2.42 5.00E-05 2.86E-04
C1orf170 Chromosome 1 open reading frame 170 chr1 901,876 917,673 8.05 1.37 2.55 5.00E-05 2.86E-04
PRPH Peripherin chr12 49,686,760 49,692,481 55.03 8.39 2.71 5.00E-05 2.86E-04
a FXYD2, FXYD6, and FXYD6-FXYD2 (readthrough) were reported as a single transcriptional locus by Cufﬂinks.
b KRT39 and KRT40 were reported as a single transcriptional locus by Cufﬂinks.
c C4A and C4B_2 were reported as a single transcriptional locus by Cufﬂinks.
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temporal, macular, and nasal regions of the retina and RPE/choroid
along with an additional sample with superior and inferior regions
represented. Distinct expression proﬁles clearly differentiated
retina from RPE/choroid. Differences between periphery and mac-
ula were more pronounced in the retina than in the RPE/choroid
and in both tissues reﬂected dominant cell type distributions. In the
neural retina, nasal and temporal regions were indistinguishable by
our criteria.2. Materials and methods
2.1. Tissue acquisition
Human eyes were obtained through the Iowa Lions Eye Bank
after informed consent by family members and in accordance with
the tenets of the Declaration of Helsinki. Donor information is
presented in Table 1. In four donors, an 8 mm trephine punch was
used to remove the macula and a 6 mm punch was used to remove
Table 3
Top 40 differentially expressed genes between temporal retina vs. macular retina with q-value < 0.001 and absolute log2(fold-change)  1.
Symbol Description Chromosome Start Stop Macular
retina
(FPKM)
Temporal
retina
(FPKM)
Log2(FC) P-value Q-value
MIR1247 MicroRNA 1247 chr14 102,023,301 102,026,828 0.30 4.16 3.77 5.00E-05 2.86E-04
CYP26B1 Cytochrome P450, family 26, subfamily B,
polypeptide 1
chr2 72,356,363 72,375,687 0.41 4.68 3.51 5.00E-05 2.86E-04
HSD17B2 Hydroxysteroid (17-beta) dehydrogenase 2 chr16 82,056,731 82,132,139 1.29 10.96 3.08 5.00E-05 2.86E-04
PRL Prolactin chr6 22,287,472 22,303,082 4.48 29.37 2.71 5.00E-05 2.86E-04
COL2A1 Collagen, type II, alpha 1 chr12 48,366,747 48,398,285 1.56 9.42 2.59 5.00E-05 2.86E-04
ZIC1 Zic family member 1 chr3 147,103,834 147,134,784 1.24 6.24 2.33 5.00E-05 2.86E-04
NDUFA4L2 NADH dehydrogenase (ubiquinone) 1 alpha
subcomplex, 4-like 2
chr12 57,623,324 57,634,949 42.98 162.00 1.91 1.00E-04 5.49E-04
FAM46B Family with sequence similarity 46, member B chr1 27,331,510 27,339,333 0.96 3.61 1.91 5.00E-05 2.86E-04
LOXL4 Lysyl oxidase-like 4 chr10 100,007,442 100,028,007 0.98 3.65 1.90 1.00E-04 5.49E-04
FXYD2a FXYD domain containing ion transport regulator 2 chr11 117,690,789 117,748,201 12.05 43.78 1.86 5.00E-05 2.86E-04
ATP1A2 ATPase, Naþ/Kþ transporting, alpha 2 polypeptide chr1 160,085,519 160,113,374 17.41 57.10 1.71 5.00E-05 2.86E-04
SIX2 SIX homeobox 2 chr2 45,232,323 45,236,563 2.44 7.92 1.70 5.00E-05 2.86E-04
GPR124 G protein-coupled receptor 124 chr8 37,654,400 37,707,431 4.99 15.61 1.65 5.00E-05 2.86E-04
ADSSL1 Adenylosuccinate synthase like 1 chr14 105,190,533 105,213,663 5.25 15.63 1.57 5.00E-05 2.86E-04
HTR1F 5-hydroxytryptamine (serotonin) receptor 1F, G
protein-coupled
chr3 87,841,874 88,049,226 0.78 2.31 1.56 5.00E-05 2.86E-04
ATOH8 Atonal homolog 8 (Drosophila) chr2 85,978,936 86,018,506 1.13 3.20 1.50 5.00E-05 2.86E-04
NPVF Neuropeptide VF precursor chr7 25,264,190 25,268,105 29.12 81.63 1.49 5.00E-05 2.86E-04
PPP1R3C Protein phosphatase 1, regulatory subunit 3C chr10 93,379,047 93,392,858 14.02 38.45 1.46 5.00E-05 2.86E-04
CLEC4F C-type lectin domain family 4, member F chr2 71,035,775 71,047,732 2.07 5.67 1.45 1.00E-04 5.49E-04
CD4 CD4 molecule chr12 6,898,637 6,929,977 5.55 14.99 1.43 5.00E-05 2.86E-04
POU4F2 POU class 4 homeobox 2 chr4 147,560,044 147,563,623 11.13 1.98 2.49 5.00E-05 2.86E-04
NEFM Neuroﬁlament, medium polypeptide chr8 24,771,273 24,776,612 544.29 94.76 2.52 5.00E-05 2.86E-04
SLC17A6 Solute carrier family 17 (vesicular glutamate
transporter), member 6
chr11 22,355,132 22,401,046 43.08 7.44 2.53 5.00E-05 2.86E-04
TTC39A Tetratricopeptide repeat domain 39A chr1 51,752,172 51,810,785 22.16 3.76 2.56 5.00E-05 2.86E-04
ISLR2 Immunoglobulin superfamily containing leucine-
rich repeat 2
chr15 74,418,236 74,429,152 15.76 2.61 2.59 5.00E-05 2.86E-04
POU4F1 POU class 4 homeobox 1 chr13 78,628,989 79,233,323 23.65 3.84 2.62 5.00E-05 2.86E-04
AHNAK2 AHNAK nucleoprotein 2 chr14 105,371,613 105,444,694 84.49 13.65 2.63 5.00E-05 2.86E-04
IRX1 Iroquois homeobox 1 chr5 3,596,054 3,601,517 5.55 0.88 2.66 5.00E-05 2.86E-04
IRX2 Iroquois homeobox 2 chr5 2,745,916 2,751,769 14.95 2.34 2.67 5.00E-05 2.86E-04
HTR1B 5-hydroxytryptamine (serotonin) receptor 1B, G
protein-coupled
chr6 78,168,875 78,174,100 3.40 0.51 2.74 5.00E-05 2.86E-04
MCTP1 Multiple C2 domains, transmembrane 1 chr5 94,036,882 94,620,279 3.33 0.50 2.75 5.00E-05 2.86E-04
Potentially novel chr6 113,745,551 113,755,041 13.32 1.90 2.81 5.00E-05 2.86E-04
CPNE9 Copine family member IX chr3 9,745,509 9,771,592 5.89 0.83 2.83 5.00E-05 2.86E-04
MRGPRE MAS-related GPR, member E chr11 3,246,156 3,254,111 12.08 1.55 2.96 5.00E-05 2.86E-04
ABO ABO blood group (transferase A, alpha 1-3-N-
acetylgalactosaminyltransferase; transferase B,
alpha 1-3-galactosyltransferase)
chr9 136,099,931 136,151,454 3.68 0.44 3.07 5.00E-05 2.86E-04
Potentially novel chr12 108,203,132 108,258,620 3.78 0.45 3.08 5.00E-05 2.86E-04
RASGRP3 RAS guanyl releasing protein 3 (calcium and DAG-
regulated)
chr2 33,630,960 33,792,285 5.84 0.62 3.24 5.00E-05 2.86E-04
C3orf55 Chromosome 3 open reading frame 55 chr3 157,260,745 157,395,552 6.11 0.60 3.34 5.00E-05 2.86E-04
PRPH Peripherin chr12 49,686,760 49,692,481 55.03 5.00 3.46 5.00E-05 2.86E-04
C1orf170 Chromosome 1 open reading frame 170 chr1 901,876 917,673 8.05 0.66 3.60 5.00E-05 2.86E-04
a FXYD2, FXYD6, and FXYD6-FXYD2 (readthrough) were reported as a single transcriptional locus by Cufﬂinks.
S.S. Whitmore et al. / Experimental Eye Research 129 (2014) 93e10696temporal and nasal punches. In one additional sample, a 4 mm
punch was used to dissect macular, nasal, temporal, superior and
inferior punches (Braun et al., 2013). Neural retina and RPE/choroid
were separated, ﬂash frozen in liquid nitrogen, and stored
at 80 C. All samples used in this study were preserved in liquid
nitrogen within 6 h of death.2.2. RNA sequencing
RNA was extracted from frozen tissue punches using a Qiagen
RNeasyMini Prep Kit (Qiagen, Valencio, CA) and kept frozenprior to
sequencing. The four temporal-macula-nasal sets were prepared
for paired-end sequencing using an Illumina TruSeq Stranded
mRNA Sample Prep Kit and sequenced on the Illumina platform in
the Genomics Division of the Iowa Institute of Human Genetics.Additional paired-end sequencing of one temporal-macula-nasal-
superior-inferior sample was performed on the Illumina platform
at HudsonAlpha Institute for Biotechnology (Huntsville, AL).2.3. Bioinformatic analysis
Sequenced reads were mapped to human genome build hg19
using TopHat2 (ver. 2.0.11; (Kim et al., 2013)), transcript structure
and abundance were estimated using Cufﬂinks (ver. 2.1.1; (Trapnell
et al., 2010)), and differential expression analysis was performed
using Cuffdiff (ver. 2.1.1; (Trapnell et al., 2013)). Quality control
analysis was performed using RNA-SeQC (ver. 1.1.7; (DeLuca et al.,
2012)). The cummeRbund package (ver. 2.4.1; (Trapnell et al.,
2012)) for R (ver. 3.0.2) was used for data visualization. Differen-
tial expression analysis was performed for the four donor samples
Table 4
Top 40 differentially expressed genes between nasal RPE/choroid vs. macular RPE/choroid with q-value < 0.001 and absolute log2(fold-change)  1.
Symbol Description Chromosome Start Stop Macular RPE/
choroid (FPKM)
Nasal RPE/
choroid (FPKM)
Log2(FC) P-value Q-value
SCG5 Secretogranin V (7B2 protein) chr15 32,933,869 32,989,298 8.80 117.88 3.74 5.00E-05 2.86E-04
TFPI2 Tissue factor pathway inhibitor 2 chr7 93,514,708 93,545,731 1.87 23.83 3.67 5.00E-05 2.86E-04
FHIT Fragile histidine triad chr3 59,733,016 61,237,133 14.79 115.57 2.97 5.00E-05 2.86E-04
RHO Rhodopsin chr3 129,247,481 129,254,187 9.49 73.90 2.96 5.00E-05 2.86E-04
MT1G Metallothionein 1G chr16 56,700,645 56,701,980 61.09 468.12 2.94 5.00E-05 2.86E-04
GNAT1 Guanine nucleotide binding protein (G
protein), alpha transducing activity
polypeptide 1
chr3 50,229,042 50,235,129 2.34 16.38 2.81 5.00E-05 2.86E-04
AIPL1 Aryl hydrocarbon receptor interacting
protein-like 1
chr17 6,327,058 6,338,519 2.44 16.67 2.77 5.00E-05 2.86E-04
TF Transferrin chr3 133,426,380 133,497,850 6.84 46.00 2.75 5.00E-05 2.86E-04
Potentially chr2 106,544,607 106,554,533 4.52 28.58 2.66 5.00E-05 2.86E-04
PRSS33 Protease, serine, 33 chr16 2,833,938 2,837,578 1.83 11.43 2.64 5.00E-05 2.86E-04
COL9A2 Collagen, type IX, alpha 2 chr1 40,766,086 40,782,939 3.20 19.90 2.64 5.00E-05 2.86E-04
ATP10Ba ATPase, class V, type 10B chr5 159,990,126 160,365,633 31.64 191.17 2.60 5.00E-05 2.86E-04
RCVRN Recoverin chr17 9,801,026 9,808,684 5.57 31.88 2.52 5.00E-05 2.86E-04
SAG S-antigen; retina and pineal gland
(arrestin)
chr2 234,210,734 234,255,703 9.56 53.93 2.50 5.00E-05 2.86E-04
KCNV2 Potassium channel, subfamily V,
member 2
chr9 2,717,525 2,730,037 1.88 10.23 2.44 5.00E-05 2.86E-04
SLC4A10 Solute carrier family 4, sodium
bicarbonate transporter, member 10
chr2 162,480,844 162,841,786 1.33 6.97 2.39 5.00E-05 2.86E-04
ALDH1A3 Aldehyde dehydrogenase 1 family,
member A3
chr15 101,420,008 101,456,897 18.69 96.70 2.37 5.00E-05 2.86E-04
ECEL1 Endothelin converting enzyme-like 1 chr2 233,344,536 233,362,207 1.43 6.55 2.20 5.00E-05 2.86E-04
SFRP1 Secreted frizzled-related protein 1 chr8 41,119,475 41,166,990 13.15 60.45 2.20 5.00E-05 2.86E-04
AKR7A3b Aldo-keto reductase family 7, member
A3 (aﬂatoxin aldehyde reductase)
chr1 19,592,475 19,616,124 0.98 4.06 2.06 1.50E-04 8.01E-04
NRN1 Neuritin 1 chr6 5,998,227 6,008,078 11.86 4.36 1.44 5.00E-05 2.86E-04
PRIMA1 Proline rich membrane anchor 1 chr14 94,184,643 94,255,079 11.83 4.13 1.52 5.00E-05 2.86E-04
CXCL14 Chemokine (C-X-C motif) ligand 14 chr5 134,906,370 134,914,969 21.66 7.49 1.53 5.00E-05 2.86E-04
SCN7A Sodium channel, voltage-gated, type
VII, alpha subunit
chr2 167,260,082 167,350,946 9.90 3.33 1.57 5.00E-05 2.86E-04
C1QL1 Complement component 1, q
subcomponent-like 1
chr17 43,036,339 43,046,605 11.94 3.90 1.62 1.50E-04 8.01E-04
TRDN Triadin chr6 123,537,304 123,958,601 24.71 7.99 1.63 5.00E-05 2.86E-04
PKHD1L1 Polycystic kidney and hepatic disease 1
(autosomal recessive)-like 1
chr8 110,374,702 110,549,447 6.81 2.19 1.64 5.00E-05 2.86E-04
GABRE Gamma-aminobutyric acid (GABA) A
receptor, epsilon
chrX 151,121,595 151,143,206 6.17 1.98 1.64 5.00E-05 2.86E-04
RGS7BP Regulator of G-protein signaling 7
binding protein
chr5 63,801,626 63,910,486 6.04 1.92 1.65 5.00E-05 2.86E-04
EPHA3 EPH receptor A3 chr3 89,156,673 89,531,390 11.95 3.72 1.69 5.00E-05 2.86E-04
CRHBP Corticotropin releasing hormone
binding protein
chr5 76,248,679 76,276,815 6.58 1.97 1.74 5.00E-05 2.86E-04
CCL14c Chemokine (CeC motif) ligand 14 chr17 34,310,691 34,329,084 208.78 62.35 1.74 5.00E-05 2.86E-04
CPAMD8 C3 and PZP-like, alpha-2-macroglobulin
domain containing 8
chr19 17,003,760 17,137,625 12.55 3.69 1.77 5.00E-05 2.86E-04
AQP7P1 Aquaporin 7 pseudogene 1 chr9 67,269,284 67,289,625 14.91 4.37 1.77 5.00E-05 2.86E-04
LOC100507387 chr5 175,542,798 175,554,408 11.01 2.77 1.99 5.00E-05 2.86E-04
POSTN Periostin, osteoblast speciﬁc factor chr13 38,136,718 38,172,981 5.91 1.45 2.02 5.00E-05 2.86E-04
NRXN1 Neurexin 1 chr2 50,145,624 51,259,674 4.18 1.00 2.06 5.00E-05 2.86E-04
SULT1E1 Sulfotransferase family 1E, estrogen-
preferring, member 1
chr4 70,706,929 70,725,870 8.30 1.82 2.19 5.00E-05 2.86E-04
WFDC1 WAP four-disulﬁde core domain 1 chr16 84,303,639 84,363,457 154.28 33.71 2.19 5.00E-05 2.86E-04
TBX15 T-box 15 chr1 119,425,665 119,543,988 5.11 1.08 2.24 5.00E-05 2.86E-04
a ATP10B and LOC285629 were reported as a single transcriptional locus by Cufﬂinks.
b AKR7A3 and AKR7L were reported as a single transcriptional locus by Cufﬂinks.
c CCL14, CCL15, CCL15-CCL14 (readthrough) were reported as a single transcriptional locus by Cufﬂinks.
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RPE/choroid). Spearman's rank correlation coefﬁcient as imple-
mented in R was used for all correlations. Genes were deemed
differentially expressed if the absolute value of the log2 (fold
change) was >1, the q-value < 0.001, and the FPKM (Fragments Per
Kilobase of transcript per Million mapped reads) values of either
group compared were all > 1.3. Results
We performed 100 bp paired-end RNA-Seq on retina and RPE/
choroid from the temporal, macular, and nasal regions of four
clinically normal human donor eyes (Table 1). Hierarchical clus-
tering of samples showed clear separation of neural retina from
RPE/choroid samples and evidence of donor effect, i.e., samples
derived from the same donor tend to cluster together more often
than not (Fig. 1) (Rouhani et al., 2014).
Table 5
Top 40 differentially expressed genes between temporal RPE/choroid vs. macular RPE/choroid with q-value < 0.001 and absolute log2(fold-change)  1.
Symbol Description Chromosome Start Stop Macular
RPE/choroid
(FPKM)
Temporal
RPE/choroid
(FPKM)
Log2(FC) P-value Q-value
TFPI2 Tissue factor pathway inhibitor 2 chr7 93,514,708 93,545,731 1.87 82.08 5.45 5.00E-05 2.86E-04
SCG5 Secretogranin V (7B2 protein) chr15 32,933,869 32,989,298 8.80 118.78 3.75 5.00E-05 2.86E-04
FHIT Fragile histidine triad chr3 59,733,016 61,237,133 14.79 194.50 3.72 5.00E-05 2.86E-04
COL9A2 Collagen, type IX, alpha 2 chr1 40,766,086 40,782,939 3.20 25.78 3.01 5.00E-05 2.86E-04
ALDH1A3 Aldehyde dehydrogenase 1 family, member A3 chr15 101,420,008 101,456,897 18.69 139.08 2.90 5.00E-05 2.86E-04
SFRP1 Secreted frizzled-related protein 1 chr8 41,119,475 41,166,990 13.15 91.25 2.79 5.00E-05 2.86E-04
Potentially novel chr2 106,544,607 106,554,533 4.52 28.78 2.67 5.00E-05 2.86E-04
ATP10Ba ATPase, class V, type 10B chr5 159,990,126 160,365,633 31.64 181.87 2.52 5.00E-05 2.86E-04
PRSS33 Protease, serine, 33 chr16 2,833,938 2,837,578 1.83 9.95 2.44 5.00E-05 2.86E-04
ECEL1 Endothelin converting enzyme-like 1 chr2 233,344,536 233,362,207 1.43 7.16 2.33 5.00E-05 2.86E-04
VIP Vasoactive intestinal peptide chr6 153,054,002 153,080,902 1.91 9.35 2.29 5.00E-05 2.86E-04
MT1G Metallothionein 1G chr16 56,700,645 56,701,980 61.09 287.71 2.24 5.00E-05 2.86E-04
PCOLCE2 Procollagen C-endopeptidase enhancer 2 chr3 142,536,701 142,608,045 2.57 12.07 2.23 5.00E-05 2.86E-04
SFRP4 Secreted frizzled-related protein 4 chr7 37,945,534 37,956,525 30.86 125.85 2.03 5.00E-05 2.86E-04
DCN Decorin chr12 91,539,034 91,576,806 102.16 403.72 1.98 5.00E-05 2.86E-04
TMEM151A Transmembrane protein 151A chr11 66,059,344 66,068,063 1.65 6.39 1.95 5.00E-05 2.86E-04
RD3 Retinal degeneration 3 chr1 211,649,102 211,667,124 1.39 5.29 1.93 5.00E-05 2.86E-04
FABP4 Fatty acid binding protein 4, adipocyte chr8 82,390,731 82,395,473 8.71 32.59 1.90 5.00E-05 2.86E-04
FXYD3 FXYD domain containing ion transport
regulator 3
chr19 35,606,414 35,615,228 24.91 88.14 1.82 5.00E-05 2.86E-04
PKP1 Plakophilin 1 chr1 201,252,579 201,302,121 3.18 10.93 1.78 5.00E-05 2.86E-04
chr4 145,664,157 145,666,550 10.80 3.89 1.47 5.00E-05 2.86E-04
AQP1b Aquaporin 1 (Colton blood group) chr7 30,791,750 30,965,131 142.63 50.74 1.49 5.00E-05 2.86E-04
NMNAT2 Nicotinamide nucleotide adenylyltransferase 2 chr1 183,217,073 183,387,634 6.38 2.19 1.54 5.00E-05 2.86E-04
KCNAB1 Potassium voltage-gated channel, shaker-
related subfamily, beta member 1
chr3 155,838,336 156,256,927 11.14 3.80 1.55 5.00E-05 2.86E-04
IGJ Immunoglobulin J polypeptide, linker protein
for immunoglobulin alpha andmu polypeptides
chr4 71,521,257 71,532,652 70.78 23.84 1.57 5.00E-05 2.86E-04
ITGA8 Integrin, alpha 8 chr10 15,555,950 15,762,323 45.26 15.18 1.58 5.00E-05 2.86E-04
POSTN Periostin, osteoblast speciﬁc factor chr13 38,136,718 38,172,981 5.91 1.94 1.60 5.00E-05 2.86E-04
LOC100507387 Non-coding RNA chr5 175,542,798 175,554,408 11.01 3.40 1.70 5.00E-05 2.86E-04
RGS7BP Regulator of G-protein signaling 7 binding
protein
chr5 63,801,626 63,910,486 6.04 1.82 1.73 5.00E-05 2.86E-04
TBX15 T-box 15 chr1 119,425,665 119,543,988 5.11 1.53 1.74 5.00E-05 2.86E-04
CPAMD8 C3 and PZP-like, alpha-2-macroglobulin domain
containing 8
chr19 17,003,760 17,137,625 12.55 3.68 1.77 5.00E-05 2.86E-04
PKD1L2 Polycystic kidney disease 1-like 2 chr16 81,134,483 81,253,975 5.61 1.64 1.78 5.00E-05 2.86E-04
SULT1E1 Sulfotransferase family 1E, estrogen-preferring,
member 1
chr4 70,706,929 70,725,870 8.30 2.35 1.82 5.00E-05 2.86E-04
TMEM132C Transmembrane protein 132C chr12 128,751,947 129,192,460 8.78 2.35 1.90 5.00E-05 2.86E-04
EPHA3 EPH receptor A3 chr3 89,156,673 89,531,390 11.95 2.77 2.11 5.00E-05 2.86E-04
CRHBP Corticotropin releasing hormone binding
protein
chr5 76,248,679 76,276,815 6.58 1.45 2.18 5.00E-05 2.86E-04
CXCL14 Chemokine (C-X-C motif) ligand 14 chr5 134,906,370 134,914,969 21.66 4.45 2.28 5.00E-05 2.86E-04
CALCB Calcitonin-related polypeptide beta chr11 15,095,145 15,100,177 7.76 0.99 2.97 5.00E-05 2.86E-04
WFDC1 WAP four-disulﬁde core domain 1 chr16 84,303,639 84,363,457 154.28 14.90 3.37 5.00E-05 2.86E-04
TRDN Triadin chr6 123,537,304 123,958,601 24.71 2.33 3.41 5.00E-05 2.86E-04
a ATP10B and LOC285629 were reported as a single transcriptional locus by Cufﬂinks.
b AQP1, FAM188B, INMT, and INMT-FAM188B (readthrough) were reported as a single transcriptional locus by Cufﬂinks.
Table 6
All differentially expressed genes between temporal RPE/choroid vs. nasal RPE/choroid with q-value < 0.001 and absolute log2(fold-change)  1.
Symbol Description Chromosome Start Stop Nasal RPE/
choroid (FPKM)
Temporal RPE/
choroid (FPKM)
Log2(FC) P-value Q-value
MPZ Myelin protein zero chr1 161,274,410 161,279,793 5.28 40.31 2.93 5.00E-05 2.86E-04
VIP Vasoactive intestinal peptide chr6 153,054,002 153,080,902 2.62 9.35 1.84 5.00E-05 2.86E-04
SCN7A Sodium channel, voltage-gated, type VII, alpha
subunit
chr2 167,260,082 167,350,946 3.33 6.72 1.01 1.50E-04 8.01E-04
WFDC1 WAP four-disulﬁde core domain 1 chr16 84,303,639 84,363,457 33.71 14.90 1.18 5.00E-05 2.86E-04
HBA2 Hemoglobin, alpha 2 chr16 222,845 223,709 139.35 56.67 1.30 5.00E-05 2.86E-04
TRDN triadin chr6 123,537,304 123,958,601 7.99 2.33 1.78 5.00E-05 2.86E-04
TULP1 Tubby like protein 1 chr6 35,465,650 35,480,663 7.68 2.21 1.80 5.00E-05 2.86E-04
TF Transferrin chr3 133,426,380 133,497,850 46.00 12.52 1.88 1.00E-04 5.49E-04
GUCA1B Guanylate cyclase activator 1B (retina) chr6 42,151,021 42,168,689 7.48 1.62 2.21 5.00E-05 2.86E-04
RCVRN Recoverin chr17 9,801,026 9,808,684 31.88 4.18 2.93 5.00E-05 2.86E-04
SAG S-antigen; retina and pineal gland (arrestin) chr2 234,210,734 234,255,703 53.93 6.09 3.15 5.00E-05 2.86E-04
GNAT1 Guanine nucleotide binding protein (G protein),
alpha transducing activity polypeptide 1
chr3 50,229,042 50,235,129 16.38 1.54 3.41 5.00E-05 2.86E-04
AIPL1 Aryl hydrocarbon receptor interacting protein-
like 1
chr17 6,327,058 6,338,519 16.67 1.53 3.44 5.00E-05 2.86E-04
RHO Rhodopsin chr3 129,247,481 129,254,187 73.90 6.61 3.48 5.00E-05 2.86E-04
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Table 7
Top 40 differentially expressed genes between macular RPE/choroid vs. macular retina with q-value < 0.001 and absolute log2(fold-change)  1.
Symbol Description Chromosome Start Stop Macular retina (FPKM) Macular RPE/
choroid (FPKM)
Log2(FC) P-value Q-value
Potentially novel chr14 106,512,071 106,518,924 0.00 322.59 Inf 5.00E-05 2.86E-04
PRRX2 Paired related homeobox 2 chr9 132,427,911 132,484,952 0.00 60.99 Inf 5.00E-05 2.86E-04
PITX1 Paired-like homeodomain 1 chr5 134,363,350 134,370,461 0.00 25.51 Inf 5.00E-05 2.86E-04
ABCB5 ATP-binding cassette, sub-
family B (MDR/TAP), member 5
chr7 20,655,244 20,796,642 0.00 21.83 Inf 5.00E-05 2.86E-04
CCL23 Chemokine (CeC motif) ligand
23
chr17 34,340,096 34,345,026 0.00 21.39 Inf 5.00E-05 2.86E-04
CPXM1 Carboxypeptidase X (M14
family), member 1
chr20 2,774,714 2,781,292 0.00 19.60 Inf 5.00E-05 2.86E-04
Potentially novel chr14 106,573,231 106,791,526 0.00 18.70 Inf 5.00E-05 2.86E-04
LOC340357 Long non-coding RNA chr8 12,623,570 12,675,830 0.00 14.19 Inf 5.00E-05 2.86E-04
Potentially novel chr2 72,375,757 72,376,046 0.00 14.09 Inf 5.00E-05 2.86E-04
GZMK Granzyme K (granzyme 3;
tryptase II)
chr5 54,320,106 54,329,960 0.00 9.88 Inf 5.00E-05 2.86E-04
Potentially novel chr11 23,099,882 23,100,568 0.00 8.98 Inf 5.00E-05 2.86E-04
SULT1E1 Sulfotransferase family 1E,
estrogen-preferring, member 1
chr4 70,706,929 70,725,870 0.00 8.30 Inf 5.00E-05 2.86E-04
CD3E CD3e molecule, epsilon (CD3-
TCR complex)
chr11 118,175,294 118,186,890 0.00 7.73 Inf 5.00E-05 2.86E-04
Potentially novel chr9 69,616,397 69,650,111 0.00 6.93 Inf 5.00E-05 2.86E-04
Potentially novel chr12 85,380,571 85,386,590 0.00 6.24 Inf 5.00E-05 2.86E-04
KCNK17 Potassium channel, subfamily
K, member 17
chr6 39,266,776 39,282,237 0.00 5.88 Inf 5.00E-05 2.86E-04
Potentially novel chr5 39,891,795 40,053,420 0.00 4.94 Inf 5.00E-05 2.86E-04
LINC00226 Long intergenic non-protein
coding RNA 226
chr14 106,573,231 106,791,526 0.00 4.93 Inf 5.00E-05 2.86E-04
Potentially novel chr5 134,374,392 134,375,704 0.00 4.50 Inf 5.00E-05 2.86E-04
CTSG Cathepsin G chr14 25,042,723 25,045,466 0.00 4.32 Inf 5.00E-05 2.86E-04
Potentially novel chr16 84,273,764 84,281,615 3.58 0.00 -Inf 5.00E-05 2.86E-04
DEFB131 Defensin, beta 131 chr4 9,446,259 9,452,240 3.61 0.00 -Inf 5.00E-05 2.86E-04
Potentially novel chr4 147,559,182 147,559,943 3.65 0.00 -Inf 5.00E-05 2.86E-04
Potentially novel chr14 48,702,743 48,793,893 3.69 0.00 -Inf 5.00E-05 2.86E-04
Potentially novel chr7 21,181,327 21,253,288 3.82 0.00 -Inf 5.00E-05 2.86E-04
LRTM2 Leucine-rich repeats and
transmembrane domains 2
chr12 1,901,122 2,032,895 4.46 0.00 -Inf 1.00E-04 5.49E-04
Potentially novel chr3 76,359,774 76,360,809 4.76 0.00 -Inf 5.00E-05 2.86E-04
Potentially novel chr12 55,403,375 55,409,332 5.28 0.00 -Inf 5.00E-05 2.86E-04
Potentially novel chr20 61,785,077 61,787,572 5.67 0.00 -Inf 5.00E-05 2.86E-04
DSCR8 Down syndrome critical region
gene 8
chr21 39,493,544 39,528,605 5.99 0.00 -Inf 5.00E-05 2.86E-04
TRPC7 Transient receptor potential
cation channel, subfamily C,
member 7
chr5 135,548,424 135,732,845 7.25 0.00 -Inf 5.00E-05 2.86E-04
CCDC172 Coiled-coil domain containing
172
chr10 118,083,939 118,139,551 7.56 0.00 -Inf 5.00E-05 2.86E-04
Potentially novel chr8 55,506,068 55,508,509 8.16 0.00 -Inf 5.00E-05 2.86E-04
Potentially novel chr1 23,280,951 23,299,340 9.02 0.00 -Inf 5.00E-05 2.86E-04
FEZF2 FEZ family zinc ﬁnger 2 chr3 62,355,295 62,360,692 9.07 0.00 -Inf 5.00E-05 2.86E-04
Potentially novel chr18 5,847,207 5,876,306 9.92 0.00 -Inf 5.00E-05 2.86E-04
POU4F2 POU class 4 homeobox 2 chr4 147,560,044 147,563,623 11.13 0.00 -Inf 5.00E-05 2.86E-04
Potentially novel chr5 178,422,323 178,423,333 12.42 0.00 -Inf 5.00E-05 2.86E-04
CACNG3 Calcium channel, voltage-
dependent, gamma subunit 3
chr16 24,266,873 24,373,737 16.08 0.00 -Inf 5.00E-05 2.86E-04
Potentially novel chr12 9,727,536 9,728,249 30.87 0.00 -Inf 5.00E-05 2.86E-04
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We compared our dataset to a recently published table of FPKM
(Fragments Per Kilobase of transcript per Million mapped reads)
values derived from macular and peripheral retina and RPE/
choroid/sclera for 91 genes implicated by genome-wide associa-
tion studies (GWAS) in various eye diseases (Li et al., 2014). To
compare the previous results to ours, we averaged our nasal and
temporal FPKM values together for one “peripheral” value (Fig. 2).
Where Cufﬂinks matched two separate loci to a single gene
symbol, we took the higher of the two values. While the values for
retina roughly follow the diagonal, FPKM values were consistently
higher for genes in our RPE/choroid samples compared to the RPE/choroid/sclera samples of Li et al., likely reﬂecting the cellular
paucity of the sclera. The obvious exception is COL10A1, which
shows higher expression in peripheral RPE/choroid/sclera than in
peripheral RPE/choroid alone. In addition, TIMP3, reported by Li
et al. as a predominantly retinal transcript, showed robust
expression in all RPE/choroid samples in the current report
(Fig. 2).
3.2. Regional gene expression by tissue
To evaluate gene expression across regions of the retina and
RPE/choroid, we used Cuffdiff to perform pairwise tests between
groups of punches (Supplemental Table 1). When comparing nasal
Table 8
Top 40 differentially expressed genes between nasal RPE/choroid vs. nasal retina with q-value < 0.001 and absolute log2(fold-change)  1.
Symbol Description Chromosome Start Stop Nasal retina
(FPKM)
Nasal RPE/choroid
(FPKM)
Log2(FC) P-value Q-value
Potentially novel chr14 106,512,071 106,518,924 0.00 142.27 Inf 5.00E-05 2.86E-04
PITX1 Paired-like homeodomain 1 chr5 134,363,350 134,370,461 0.00 19.53 Inf 5.00E-05 2.86E-04
LOC340357 Long non-coding RNA chr8 12,623,570 12,675,830 0.00 10.88 Inf 5.00E-05 2.86E-04
GZMK Granzyme K (granzyme 3;
tryptase II)
chr5 54,320,106 54,329,960 0.00 8.65 Inf 5.00E-05 2.86E-04
KCNK17 Potassium channel, subfamily
K, member 17
chr6 39,266,776 39,282,237 0.00 8.45 Inf 5.00E-05 2.86E-04
CCL23 Chemokine (CeC motif) ligand
23
chr17 34,340,096 34,345,026 0.00 7.03 Inf 5.00E-05 2.86E-04
Potentially novel chr5 39,891,795 40,053,420 0.00 6.18 Inf 5.00E-05 2.86E-04
TEX41 Testis expressed 41 (non-
protein coding)
chr2 145,425,533 146,021,001 0.00 5.35 Inf 5.00E-05 2.86E-04
Potentially novel chr14 22,320,484 22,323,708 0.00 4.66 Inf 5.00E-05 2.86E-04
Potentially novel chr5 134,374,392 134,375,704 0.00 3.67 Inf 5.00E-05 2.86E-04
KLRB1 Killer cell lectin-like receptor
subfamily B, member 1
chr12 9,747,869 9,760,497 0.00 3.53 Inf 5.00E-05 2.86E-04
CCL13 Chemokine (CeC motif) ligand
13
chr17 32,683,470 32,685,629 0.00 3.52 Inf 5.00E-05 2.86E-04
Potentially novel chr18 3,466,243 3,478,970 0.00 2.99 Inf 5.00E-05 2.86E-04
LMX1B LIM homeobox transcription
factor 1, beta
chr9 129,376,673 129,463,311 0.00 2.93 Inf 5.00E-05 2.86E-04
SLAMF7 SLAM family member 7 chr1 160,709,032 160,725,021 0.00 1.57 Inf 5.00E-05 2.86E-04
ZG16B Zymogen granule protein 16B chr16 2,880,172 2,882,285 0.00 1.53 Inf 5.00E-05 2.86E-04
SAA1 Serum amyloid A1 chr11 18,287,807 18,291,523 0.45 2255.58 12.30 5.00E-05 2.86E-04
PLA2G2A Phospholipase A2, group IIA
(platelets, synovial ﬂuid)
chr1 20,301,923 20,306,932 0.27 553.86 11.01 5.00E-05 2.86E-04
ABCB5 ATP-binding cassette, sub-
family B (MDR/TAP), member 5
chr7 20,655,244 20,796,642 0.01 18.83 10.65 1.50E-04 8.01E-04
PLVAP Plasmalemma vesicle
associated protein
chr19 17,462,251 17,488,137 0.09 122.71 10.47 5.00E-05 2.86E-04
KCNC2 Potassium voltage-gated
channel, Shaw-related
subfamily, member 2
chr12 75,433,857 75,603,528 17.88 0.18 6.60 5.00E-05 2.86E-04
NEFM Neuroﬁlament, medium
polypeptide
chr8 24,771,273 24,776,612 169.15 1.71 6.63 5.00E-05 2.86E-04
CNGA3 Cyclic nucleotide gated channel
alpha 3
chr2 98,703,594 99,016,789 4.16 0.04 6.67 5.00E-05 2.86E-04
RASGRF1 Ras protein-speciﬁc guanine
nucleotide-releasing factor 1
chr15 79,252,288 79,383,265 14.36 0.14 6.69 5.00E-05 2.86E-04
CACNG5 Calcium channel, voltage-
dependent, gamma subunit 5
chr17 64,831,229 64,890,871 19.03 0.18 6.72 5.00E-05 2.86E-04
AGBL4 ATP/GTP binding protein-like 4 chr1 48,998,369 50,489,626 2.06 0.02 6.76 5.00E-05 2.86E-04
Potentially novel chr10 3,675,719 3,690,589 7.93 0.05 7.41 5.00E-05 2.86E-04
CRYAA Crystallin, alpha A chr21 44,570,160 44,592,913 318.89 1.65 7.59 5.00E-05 2.86E-04
C6orf7 Chromosome 6 open reading
frame 7
chr6 80,472,023 80,580,137 2.24 0.01 8.22 5.00E-05 2.86E-04
Potentially novel chr6 89,881,239 89,881,908 1.30 0.00 -Inf 5.00E-05 2.86E-04
LEMD1 LEM domain containing 1 chr1 205,342,379 205,436,588 1.54 0.00 -Inf 5.00E-05 2.86E-04
Potentially novel chr9 32,865,800 32,909,556 2.00 0.00 -Inf 5.00E-05 2.86E-04
Potentially novel chr17 5,000,474 5,000,915 2.59 0.00 -Inf 5.00E-05 2.86E-04
Potentially novel chr11 3,599,999 3,602,427 2.82 0.00 -Inf 5.00E-05 2.86E-04
Potentially novel chr1 10,873,924 10,874,785 3.12 0.00 -Inf 5.00E-05 2.86E-04
Potentially novel chr16 84,273,764 84,281,615 3.15 0.00 -Inf 5.00E-05 2.86E-04
Potentially novel chr1 91,183,265 91,183,539 3.39 0.00 -Inf 5.00E-05 2.86E-04
C1orf141 Chromosome 1 open reading
frame 141
chr1 67,557,494 67,607,567 3.55 0.00 -Inf 5.00E-05 2.86E-04
Potentially novel chr10 81,657,061 81,657,275 3.67 0.00 -Inf 5.00E-05 2.86E-04
DEFB131 Defensin, beta 131 chr4 9,446,259 9,452,240 4.55 0.00 -Inf 5.00E-05 2.86E-04
S.S. Whitmore et al. / Experimental Eye Research 129 (2014) 93e106100retina vs. macular retina, 30 genes showed increased expression in
nasal retina and 128 genes showed decreased expression (Table 2).
When comparing temporal retina vs. macular retina, 37 genes
showed increased expression in temporal retina and 323 genes
showed decreased expression (Table 3). Notably, of the 40 top dif-
ferences in expression between nasal retina and macular retina
(Table 2), 21 of the same genes were in the list of top 40 differences
between temporal retina and macular retina (Table 3). Interest-
ingly, no geneswere differentially expressed between temporal andnasal retina, suggesting that these two regions of the retina are
molecularly indistinguishable using these criteria.
In the nasal vs. macular RPE/choroid comparison, 81 genes
showed increased expression in the nasal RPE/choroid and 39
genes showed decreased expression (Table 4). When comparing
temporal vs. macular RPE/choroid, 70 genes were increased in the
temporal RPE/choroid and 44 genes were decreased (Table 5). In
contrast to the retina, in which no gene expression differences
between different peripheral regions met our criteria for
Table 9
Top 40 differentially expressed genes between temporal RPE/choroid vs. temporal retina with q-value < 0.001 and absolute log2(fold-change)  1.
Symbol Description Chromosome Start Stop Temporal retina
(FPKM)
Temporal RPE/
choroid
(FPKM)
Log2(FC) P-value Q-value
Potentially novel chr14 106,512,071 106,518,924 0.00 192.09 Inf 5.00E-05 2.86E-04
PITX1 Paired-like
homeodomain 1
chr5 134,363,350 134,370,461 0.00 19.83 Inf 5.00E-05 2.86E-04
LOC340357 Long non-coding RNA chr8 12,623,570 12,675,830 0.00 14.87 Inf 5.00E-05 2.86E-04
PAX3 Paired box 3 chr2 223,064,605 223,169,936 0.00 13.21 Inf 5.00E-05 2.86E-04
AKR1B10 Aldo-keto reductase
family 1, member B10
(aldose reductase)
chr7 134,200,788 134,226,166 0.00 8.67 Inf 5.00E-05 2.86E-04
GZMK Granzyme K (granzyme
3; tryptase II)
chr5 54,320,106 54,329,960 0.00 8.60 Inf 5.00E-05 2.86E-04
Potentially novel chr1 170,632,134 170,633,074 0.00 8.30 Inf 5.00E-05 2.86E-04
Potentially novel chr5 39,891,795 40,053,420 0.00 7.70 Inf 5.00E-05 2.86E-04
FOXD3 Forkhead box D3 chr1 63,786,575 63,790,797 0.00 6.14 Inf 5.00E-05 2.86E-04
TEX41 Testis expressed 41
(non-protein coding)
chr2 145,425,533 146,021,001 0.00 5.47 Inf 5.00E-05 2.86E-04
Potentially novel chr11 23,099,882 23,100,568 0.00 5.43 Inf 5.00E-05 2.86E-04
CLEC10A C-type lectin domain
family 10, member A
chr17 6,977,855 6,983,826 0.00 4.53 Inf 5.00E-05 2.86E-04
LCK LCK proto-oncogene,
Src family tyrosine
kinase
chr1 32,716,839 32,751,766 0.00 3.57 Inf 5.00E-05 2.86E-04
LMX1B LIM homeobox
transcription factor 1,
beta
chr9 129,376,673 129,463,311 0.00 3.50 Inf 5.00E-05 2.86E-04
Potentially novel chr9 69,616,397 69,650,111 0.00 3.46 Inf 5.00E-05 2.86E-04
S1PR5 Sphingosine-1-
phosphate receptor 5
chr19 10,623,417 10,628,668 0.00 3.27 Inf 5.00E-05 2.86E-04
CLIC3 Chloride intracellular
channel 3
chr9 139,889,059 139,891,024 0.00 3.18 Inf 5.00E-05 2.86E-04
Potentially novel chr5 134,374,392 134,375,704 0.00 3.17 Inf 5.00E-05 2.86E-04
Potentially novel chr18 3,466,243 3,478,970 0.00 2.72 Inf 5.00E-05 2.86E-04
CCL13 Chemokine (CeC motif)
ligand 13
chr17 32,683,470 32,685,629 0.00 2.56 Inf 5.00E-05 2.86E-04
Potentially novel chr11 117,673,186 117,673,498 3.81 0.00 -Inf 5.00E-05 2.86E-04
C1orf141 Chromosome 1 open
reading frame 141
chr1 67,557,494 67,607,567 3.83 0.00 -Inf 5.00E-05 2.86E-04
Potentially novel chr18 76,736,580 76,739,475 4.33 0.00 -Inf 5.00E-05 2.86E-04
NAT16 N-acetyltransferase 16
(GCN5-related,
putative)
chr7 100,813,667 100,823,557 4.36 0.00 -Inf 5.00E-05 2.86E-04
C16orf11 Chromosome 16 open
reading frame 11
chr16 610,179 615,529 4.39 0.00 -Inf 5.00E-05 2.86E-04
Potentially novel chr12 55,403,375 55,409,332 4.56 0.00 -Inf 5.00E-05 2.86E-04
Potentially novel chr1 10,873,924 10,874,785 4.76 0.00 -Inf 5.00E-05 2.86E-04
Potentially novel chr17 77,818,917 77,825,465 4.77 0.00 -Inf 5.00E-05 2.86E-04
Potentially novel chr3 192,862,226 192,894,687 5.02 0.00 -Inf 5.00E-05 2.86E-04
DEFB131 Defensin, beta 131 chr4 9,446,259 9,452,240 5.46 0.00 -Inf 5.00E-05 2.86E-04
Potentially novel chr7 127,116,864 127,146,567 6.15 0.00 -Inf 5.00E-05 2.86E-04
Potentially novel chr7 21,181,327 21,253,288 6.30 0.00 -Inf 5.00E-05 2.86E-04
Potentially novel chr1 23,280,951 23,299,340 6.93 0.00 -Inf 5.00E-05 2.86E-04
MIR124-3 MicroRNA 124-3 chr20 61,808,787 61,813,324 6.97 0.00 -Inf 5.00E-05 2.86E-04
Potentially novel chr20 61,785,077 61,787,572 9.70 0.00 -Inf 5.00E-05 2.86E-04
Potentially novel chr8 55,506,068 55,508,509 11.21 0.00 -Inf 5.00E-05 2.86E-04
Potentially novel chr5 178,422,323 178,423,333 11.40 0.00 -Inf 5.00E-05 2.86E-04
Potentially novel chr9 2,734,043 2,734,455 16.22 0.00 -Inf 5.00E-05 2.86E-04
DEFB119 Defensin, beta 119 chr20 29,964,965 29,978,452 56.91 0.00 -Inf 5.00E-05 2.86E-04
Potentially novel chr12 9,727,536 9,728,249 58.97 0.00 -Inf 5.00E-05 2.86E-04
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increased in the nasal RPE/choroid and 11 were decreased when
comparing temporal vs. nasal RPE/choroid (Table 6). Higher
expression of neuroretinal genes (e.g., RHO, RCVRN, SAG) in the
nasal RPE/choroid group as compared to the macular (Table 4) or
temporal (Table 6) RPE/choroid groups is traceable to the slight
but detectable neuroretinal contamination of the nasal RPE/
choroid from donor 2.We also performed comparisons between tissues within a re-
gion. We observed 2747 genes with increased expression and 2053
genes with decreased expression when comparing macular RPE/
choroid vs. macular retina (Table 7). We observed 2842 genes with
increased expression and 1935 genes with decreased expression
when comparing nasal RPE/choroid vs. nasal retina (Table 8). We
observed 2762 genes with increased expression and 1909 genes
with decreased expression when comparing temporal RPE/choroid
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Fig. 3. Intersection between differentially expressed genes sets. (A) Regional pairwise comparisons in the retina. (B) Regional pairwise comparisons in the RPE/choroid. (C) RPE/
choroid compared to retina for each region without respect to direction of fold change.
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differentially expressed genes in these comparisons.3.3. Regional expression differences for speciﬁc retinal cell types
To explore regional differences in cell types in the retina, we
mapped 92 genes identiﬁed by Siegert and coworkers as cell type
speciﬁc in mouse retina (Siegert et al., 2012) to 78 human genes in
our dataset (we required genes with human homologs to be
expressed above FPKM 0 in at least half of our human retina sam-
ples). As indicated in Fig. 4, all fourmacula samples cluster together,
while nasal and temporal samples are intermixed. All photore-
ceptor genes are enriched in the peripheral samples, whereas
several genes of ganglion cell and amacrine cells are interleaved in a
macula-enriched cluster.3.4. RPE-speciﬁc and endothelium associated gene expression in the
RPE/choroid
To compare cell populations in the RPE/choroid, we selected
predeﬁned RPE-speciﬁc and endothelium associated genes sets
(Whitmore et al., 2013) and assessed trends in expression across
temporal, macular, and nasal RPE/choroid punches (Fig. 5). The
RPE-speciﬁc set shows an overall lower expression in the macula
while the endothelium associated set shows higher expression in
the macula.3.5. Intradonor variation in ﬁve regions of the retina
In a separate experiment, we took retinal punches frommacula,
superior, inferior, temporal, and nasal regions of a single human
donor eye and performed pairwise correlation for all genes
expressed above FPKM 1 in a least one punch. Macula as compared
to any of the peripheral punches showed the greatest dispersion
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Fig. 4. Clustering of cell-type speciﬁc genes in the retina. Lighter shading indicates
higher expression while darker shading indicates lower expression (FPKM values after
row scaling). Hierarchical clustering was performed with complete linking on
Spearman rank correlation distance.
S.S. Whitmore et al. / Experimental Eye Research 129 (2014) 93e106 103from the diagonal (r from 0.97 to 0.98; Fig. 6). All peripheral vs.
peripheral comparisons were also highly correlated, (r¼ 0.99), with
modest dispersion from the diagonal in the superior vs. nasal and
nasal vs. inferior comparisons.
4. Discussion
Here we present the ﬁrst RNA-Seq dataset to separately inves-
tigate gene expression in the macula, nasal, and temporal human
retina and RPE/choroid. While intriguing differences between the
peripheral and the macular tissues were found, we did not observe
signiﬁcant differences between nasal and temporal retina. Only a
few genes were differentially expressed between nasal and tem-
poral RPE/choroid. Thus, the use of either nasal or temporal retina
as general surrogates of “peripheral” retina seems warranted based
on these data.
4.1. Limitations of the current study
RNA-Seq provides a wealth of data from each sample but
interpreting these data remains challenging. The most commonly
used measurement of expression, fragments per kilobase mapped
per million reads (FPKM), should not be interpreted as a straight-
forward reﬂection of the number of RNA molecules within a givencell or tissue punch. Moreover, as any RNA-Seq derived expression
estimate is fundamentally based on digital read counts, Gaussian
models used for microarray analysis do not apply. To reduce false
positives, we selected stringent thresholds for calling a gene as
differentially expressed, likely missing some biologically relevant
true positive events. Several neural retina genes, including RHO,
RCVRN, and SAG, showed increased expression in the nasal RPE/
choroid. This is likely due to incomplete separation of neural retina
from the RPE during dissection, a problem widely reported in
previous studies of ocular gene expression. Moreover, a larger
sample size may provide enough power to detect transcriptome-
level difference between nasal and temporal retina. However,
despite our sample size, our data showed strong rank correlations
with published FPKM values of peripheral and macular retina and
RPE/choroid/sclera (Li et al., 2014).4.2. Molecular determinants of the macula
Identifying the molecular determinants of the macular-
peripheral distinction remains an open challenge in vision
research. We found several transcription factors that were differ-
entially expressed in the macula and periphery. For instance, FOXI3
was upregulated in the nasal retina compared to themacular retina,
whereas IRX2 was downregulated in this comparison. SIX2 was
upregulated in the temporal retina compared to the macular retina,
whereas POU4F1, POU4F2, IRX1, and IRX2 were downregulated in
this comparison. POU4F1 and its target, RIT2 (Zhang et al., 2013), are
enriched in retinal ganglion cells (Kim et al., 2006), and both genes
were signiﬁcantly enriched in our macular retina samples. RIT2 is
also expressed in themouse inner nuclear layer (Zhang et al., 2013).4.3. Implications for vasculature in the retina and RPE/choroid
We observed decreased expression of prolactin (PRL) in the
macular neuroretina as compared to either peripheral region.
Prolactin is anti-angiogenic in the retina (Aranda et al., 2005), and
systemic prolactin levels correlate with diabetic retinopathy
(Arnold et al., 2010). Previous studies in rats and green monkeys
have shown that PRL is expressed throughout the cell layers of the
neural retina, and its receptor, PRLR, is expressed in photoreceptor
nuclei, inner nuclear layer, and ganglion cell layer (Rivera et al.,
2008). To our knowledge, this is the ﬁrst dataset showing
macular-peripheral differential expression of PRL in the retina.
Distribution of PRL and other regulators of angiogenesis may help
to explain the tendency of choroidal neovascular membranes to
grow towards the fovea (Klein et al., 1989; de Jong, 2006), partic-
ularly if the neovascular membrane had breached the RPE or if RPE
barrier function was compromised.
Of our predeﬁned endothelium associated gene set, MGP (ma-
trix Gla protein) showed the highest expression in the RPE/choroid.
MGPmay prevent calciﬁcation in the choroidal stroma or in Bruch's
membrane (Booij et al., 2010). Recently, Gonzalez and coworkers
used the MGP promoter to drive expression of b-galactosidase in a
gene vector in anterior pole cultures of human donor eyes
(Gonzalez et al., 2004). They observed localized expression in the
trabecular meshwork (Gonzalez et al., 2004). However, they did not
examine the tissues of the posterior pole. The Ocular Tissue Data-
base (Wagner et al., 2013) entry for MGP (available at https://
genome.uiowa.edu/otdb/) shows relatively high expression in the
RPE/choroid, on par with the trabecular meshwork, ciliary body,
and iris, and low expression in the retina, consistent with our
ﬁndings. Further study will be needed to determine the extent to
which MGP contributes to Bruch's membrane and/or choroidal
elasticity.
Fig. 5. Expression of RPE-speciﬁc and endothelium associated gene sets across regions of the RPE/choroid.
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We also observed robust expression of TIMP3 in our dataset,
compared to FPKM values of 0 in the RPE/choroid in that of Li et al.
These authors noted that expression of TIMP3 was almost entirely
limited to the retina. This result may be a side effect of the algo-
rithm used by Cufﬂinks. When Cufﬂinks estimates FPKM values, it
ﬁrst computes “fragment bundles.” Extremely high bundle values
can cause difﬁculty for the algorithm; thus, Cufﬂinks labels such
genes as “HIDATA” and does not estimate FPKMs. In our initial
analysis, we failed to detect RHO in both nasal and temporal retina.
However, inspection of individual alignment ﬁles for these samples
showed robust expression, with read counts in excess of 40,000
across the RHO transcript in temporal samples (Supplemental
Figure S1). Further investigation revealed that identiﬁed expres-
sion of TTR also marked by the “HIDATA” criterion in the nasal RPE/
choroid. Setting the “–max_bundle_frags” parameter for Cufﬂinks
and Cuffdiff to an arbitrarily high value (e.g., 20,000,000) removed
the “HIDATA” label, resulting in FPKM estimates for RHO and TTR in
all groups.4.5. Utility of ophthalmic expression datasets
Linkage studies have identiﬁed many disease loci in families
affected by macular dystrophies or other eye diseases (see exam-
ples at RetNet [https://sph.uth.edu/retnet/] and Online Mendelian
Inheritance in Man [http://omim.org/]). Causative mutations have
yet to be pinpointed within several of these loci, which cover
megabases of the genome and contain dozens of genes. Multi-
tissue regional ophthalmic datasets, such as we present here, may
help reduce the search space for candidate genes, especially fordiseases with region-speciﬁc or tissue-speciﬁc phenotypes. More-
over, as more Mendelian diseases with coding mutations are
solved, identifying silent mutations and changes in regulatory re-
gions is the remaining frontier for molecular genetics. For instance,
in 2002 Schulz and coworkers examined NPVF (formerly C7orf9) for
coding sequence changes that could explain Cystoid Macular
Edema (chr7:7,300,000e28,800,000; OMIM 153880). They found
no deleterious SNPs in the coding sequence of NPVF, but they
acknowledged that the promoter sequence may harbor the causa-
tive mutation (Schulz et al., 2002). In our data, we observe signif-
icant macular enrichment of NPVF as compared to both nasal and
temporal retina, suggesting that promoter changes could alter the
region-speciﬁc expression of NPVF in the retina.
MAK-related RP (OMIM 614181) tends to spare the temporal
retina while damaging the inferior and nasal retina (Stone et al.,
2011; Tucker et al., 2011). While we observed lower expression of
MAK in the macula (Fig. 7A), similar to many other photoreceptor
cell speciﬁc genes (Fig. 4), differences in peripheral regions of the
retina were not detected. This suggests that the regional degener-
ation observed inMAK-related RP is likely due to the distribution of
substrates or factors regulating MAK function rather than differ-
ences in gene expression across retinal topography.
BEST1, the gene mutated in Best vitelliform macular dystrophy
(OMIM 153700), has previously been shown to be expressed at
lower levels in the macular RPE/choroid than in the periphery by
immunohistochemistry, quantitative PCR, and proteomics (Mullins
et al., 2007; Skeie and Mahajan, 2014). We observed a similar
pattern of expression in our data (Figs. 5 and 7B). However, com-
parable proﬁles were seen for many other RPE-speciﬁc genes,
including RPE65, a gene previously shown to have relatively equal
abundance between macular and peripheral RPE/choroid (Kociok
Fig. 6. Intradonor region variability across ﬁve regions of the retina.
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in Fig. 5, is that normalization should be performed using cell-type
speciﬁc geneswith relatively consistent expression across anatomic
regions.
5. Conclusion
We have presented a comprehensive, transcriptome-wide view
of gene expression across the neural retina and RPE/choroid in
three regions of the retina. Gene expression in the retina correlates
with the anatomic distribution of rod photoreceptors and ganglion
cells in the macula and periphery. RPE-speciﬁc and endothelium
associated gene expression in the RPE/choroid appear inversely
related, with RPE-speciﬁc genes expressed at a lower level in the
macula than at the periphery, whereas endothelium associated
genes show slightly higher expression in the macula than in the
periphery. Additional RNA-Seq datasets for ophthalmic tissues will
facilitatemore complex analyses, includingmapping retina-speciﬁc
transcriptional regulatory circuits and identifying lowly expressed
exons.
Both analyses will facilitate the search for novel disease causing
mutations. For example, we previously used the ﬁve region RNA-
Seq data to identify rare alternative exons in ABCA4, screened a
cohort of patients with clinical evidence of ABCA4 disease for var-
iants in these exons, and identiﬁed novel splice-site mutations not
found in controls (Braun et al., 2013). To advance similar studies, we
are making our samples available on the database of Genotypes and
Phenotypes (dbGAP).
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